DE602005022613D1 - 2,3,4-substituierte cyclopentanone als therapeutische mittel - Google Patents

2,3,4-substituierte cyclopentanone als therapeutische mittel

Info

Publication number
DE602005022613D1
DE602005022613D1 DE602005022613T DE602005022613T DE602005022613D1 DE 602005022613 D1 DE602005022613 D1 DE 602005022613D1 DE 602005022613 T DE602005022613 T DE 602005022613T DE 602005022613 T DE602005022613 T DE 602005022613T DE 602005022613 D1 DE602005022613 D1 DE 602005022613D1
Authority
DE
Germany
Prior art keywords
substituierte
cyclopentanone
als
therapeutische mittel
therapeutische
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005022613T
Other languages
German (de)
English (en)
Inventor
Yariv Donde
Mark Holobiski
Mari F Posner
Robert M Burk
Michael E Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602005022613D1 publication Critical patent/DE602005022613D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
DE602005022613T 2004-11-23 2005-11-21 2,3,4-substituierte cyclopentanone als therapeutische mittel Expired - Lifetime DE602005022613D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/997,039 US7183324B2 (en) 2004-11-23 2004-11-23 2,3,4-substituted cyclopentanones as therapeutic agents
PCT/US2005/042428 WO2006058063A1 (en) 2004-11-23 2005-11-21 2,3,4-substituted-cyclopentanones as therapeutic agents

Publications (1)

Publication Number Publication Date
DE602005022613D1 true DE602005022613D1 (en) 2010-09-09

Family

ID=36087629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022613T Expired - Lifetime DE602005022613D1 (en) 2004-11-23 2005-11-21 2,3,4-substituierte cyclopentanone als therapeutische mittel

Country Status (11)

Country Link
US (1) US7183324B2 (https=)
EP (1) EP1814848B9 (https=)
JP (1) JP5114205B2 (https=)
AT (1) ATE475643T1 (https=)
AU (1) AU2005309605B2 (https=)
BR (1) BRPI0518299A2 (https=)
CA (1) CA2588599A1 (https=)
DE (1) DE602005022613D1 (https=)
DK (1) DK1814848T3 (https=)
ES (1) ES2347808T3 (https=)
WO (1) WO2006058063A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
US7781465B2 (en) * 2007-08-21 2010-08-24 Allergan, Inc. Therapeutic oxazolidinones and thiazolidinones
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
CN106928121B (zh) * 2015-12-29 2020-05-12 暨南大学 3-取代-苯并五元杂环-2-羰基化合物的高效制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
DE2715838A1 (de) 1977-04-05 1978-10-19 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4131738A (en) 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
OA12533A (en) 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP4520738B2 (ja) 2001-06-14 2010-08-11 アラーガン インコーポレイテッド 眼圧降下剤としての３、７、または３および７チアまたはオキサプロスタン酸誘導体
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents

Also Published As

Publication number Publication date
AU2005309605A1 (en) 2006-06-01
US7183324B2 (en) 2007-02-27
DK1814848T3 (da) 2010-11-08
ATE475643T1 (de) 2010-08-15
BRPI0518299A2 (pt) 2008-11-11
AU2005309605B2 (en) 2012-08-23
CA2588599A1 (en) 2006-06-01
JP5114205B2 (ja) 2013-01-09
US20060111430A1 (en) 2006-05-25
EP1814848A1 (en) 2007-08-08
EP1814848B1 (en) 2010-07-28
EP1814848B9 (en) 2011-12-21
WO2006058063A1 (en) 2006-06-01
ES2347808T3 (es) 2010-11-04
ES2347808T9 (es) 2011-06-13
JP2008520737A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
WO2004113277A3 (en) Methods and compositions for treating amyloid-related diseases
TW200714583A (en) Substituted gamma lactams as therapeutic agents
IL175953A (en) Derivatives of 3-Cycloalkylaminopyrrolidine, their Pharmaceutical Salts and Preparations Containing Them
WO2004103973A8 (en) Phenyl quinolines and their use as estrogen receptor modulators
WO2005065645A3 (en) Donepezil formulations
MXPA06001592A (es) Derivados de (4-hidroxifenil)-1h-indol-3-carbaldehido oxima como agentes estrogenicos.
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
UA94065C2 (en) Dihydropseudoerythromycin derivatives
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
DE602005022613D1 (en) 2,3,4-substituierte cyclopentanone als therapeutische mittel
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
AU2003239389A1 (en) Opioid receptor antagonists
MX2007007613A (es) Formulaciones farmaceuticas.
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
TW200531686A (en) Pharmaceutical compositions
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200602295A (en) Organic compounds
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
NO20074167L (no) Peptidiske forbindelser
WO2005060981A3 (en) Pharmaceutical compositions
WO2006052880A3 (en) Synergistic effects of combined administration of mirtazapine and a stimulant compound
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2005023188A3 (en) Compounds and methods